antihemophilic factor

(redirected from Advate)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for antihemophilic factor

a coagulation factor (trade name Hemofil) whose absence is associated with hemophilia A

References in periodicals archive ?
In addition, it had a longer half-life than Advate, which could potentially reduce the frequency of injections needed by hemophilia patients.
The product is built on the full-length ADVATE molecule, a treatment for hemophilia A already in use for more than 13 years.
ADYNOVATE, which is built on the full-length ADVATE molecule, provides proven prophylaxis with simple, twice-weekly dosing for children and adult patients with hemophilia A, helping to further individualize options for this patient population.
Comments: Hematology revenues were $855 million, excluding the impact of foreign exchange, grew 6% in the quarter driven by ADVATE, a treatment for hemophilia A, and double-digit growth of FEIBA, an inhibitor treatment.
Regenerative goods garnered $527 million for the segment, a 19 percent increase compared with 2009, while recombinant products (boosted by increased sales of Advate) amassed $2 billion for Baxter.
The product was well tolerated and demonstrated a prolonged half-life compared to Advate (anti-haemophilic factor recombinant, plasma/albumin-free method, rFVIII) by US-based Baxter International Inc (NYSE: BAX).
This growth was driven by double-digit increases across all product categories, including record sales of ADVATE, Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM) for the treatment of hemophilia A, which exceeded $1.2 billion for the year.
Continued adoption of Baxter's advanced recombinant therapy, Advate, largely was responsible for generating $2 billion in recombinant product sales last year, a 5 percent increase compared with the $1.9 billion those products garnered in 2008 and a 20 percent jump compared with the $1.7 billion posted in 2007.
This growth was driven by record sales of ADVATE, Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM) for the treatment of hemophilia A, antibody therapy products, including GAMMAGARD LIQUID(TM) [Immune Globulin Intravenous (Human)] (IVIG) 10% Solution for the treatment of primary immunodeficiencies, specialty plasma therapeutics and biosurgery products.
The company said ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] is the only extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on the demonstrated efficacy of ADVATE [Antihemophilic Factor (Recombinant)].
ADVATE, the company's recombinant factor VIII (rFVIII) for the
In the United States and Canada, Baxter also launched Baxject II, a needleless transfer device with built-in filters for Advate. In February 2007, the FDA also cleared Baxter's upgraded Ipump Pain Management System.
Sales growth in this business was driven by a 15 percent increase in the recombinant business, including $162 million of sales of ADVATE, Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM) for the treatment of hemophilia A.